创新-话题@MedSci

#创新#

1015篇内容 | 2779人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1286132, encodeId=fa1912861328b, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=中华医学会糖尿病学分会|南方医科大学沈洁教授：院内血糖管理模式探索及创新, objectType=article, longId=739767, objectId=1ee8e397673a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ee8e397673a, replyNumber=0, likeNumber=47, createdTime=2022-09-19, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ee8e397673a, moduleTitle=中华医学会糖尿病学分会|南方医科大学沈洁教授：院内血糖管理模式探索及创新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ee8e397673a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286131, encodeId=252312861311c, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=室性心律失常治疗策略全面升级，中医药创新给出中国化防治方案, objectType=article, longId=739201, objectId=d8b7e3920181, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8b7e3920181, replyNumber=0, likeNumber=64, createdTime=2022-09-15, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8b7e3920181, moduleTitle=室性心律失常治疗策略全面升级，中医药创新给出中国化防治方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8b7e3920181)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286129, encodeId=fbe9128612960, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=【日程更新】第四届创新药高峰论坛暨免疫治疗新药前沿论坛, objectType=article, longId=738820, objectId=5847e38820e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5847e38820e1, replyNumber=0, likeNumber=41, createdTime=2022-09-11, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5847e38820e1, moduleTitle=【日程更新】第四届创新药高峰论坛暨免疫治疗新药前沿论坛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5847e38820e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286130, encodeId=d348128613089, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=ESMO 2022：创新药物、创新疗法，精彩荟萃, objectType=article, longId=738627, objectId=a5c6e3862703, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5c6e3862703, replyNumber=0, likeNumber=48, createdTime=2022-09-10, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5c6e3862703, moduleTitle=ESMO 2022：创新药物、创新疗法，精彩荟萃, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5c6e3862703)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286128, encodeId=d40b1286128e7, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=烧伤领域新动能！颠覆式创新产品PermeaDerm®实现创面修复, objectType=article, longId=737846, objectId=0b81e3784640, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b81e3784640, replyNumber=0, likeNumber=47, createdTime=2022-09-06, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b81e3784640, moduleTitle=烧伤领域新动能！颠覆式创新产品PermeaDerm®实现创面修复, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b81e3784640)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286127, encodeId=9d27128612e2a, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=明明是心脏病，怎么会中风？！都是房颤惹的祸——心脏专家呼吁早发现、早治疗，提高房颤创新药物可及性, objectType=article, longId=736327, objectId=e01ae363276e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e01ae363276e, replyNumber=0, likeNumber=40, createdTime=2022-08-21, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e01ae363276e, moduleTitle=明明是心脏病，怎么会中风？！都是房颤惹的祸——心脏专家呼吁早发现、早治疗，提高房颤创新药物可及性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e01ae363276e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286126, encodeId=bdcd128612691, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=《梅斯药说》第十期药企数字化创新的蜕变和突围, objectType=article, longId=736292, objectId=ed80e3629260, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed80e3629260, replyNumber=0, likeNumber=59, createdTime=2022-08-21, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed80e3629260, moduleTitle=《梅斯药说》第十期药企数字化创新的蜕变和突围, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed80e3629260)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286125, encodeId=15c9128612556, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=《梅斯药说》第五期 “聊聊肿瘤创新药那些事儿”, objectType=article, longId=736283, objectId=e4dae3628333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4dae3628333, replyNumber=0, likeNumber=43, createdTime=2022-08-21, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4dae3628333, moduleTitle=《梅斯药说》第五期 “聊聊肿瘤创新药那些事儿”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4dae3628333)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286124, encodeId=ad881286124a7, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=上海生物医药创新企业自主研发的新冠 mRNA疫苗一期临床试验入组完毕, objectType=article, longId=735859, objectId=3eebe358592e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eebe358592e, replyNumber=0, likeNumber=56, createdTime=2022-08-16, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eebe358592e, moduleTitle=上海生物医药创新企业自主研发的新冠 mRNA疫苗一期临床试验入组完毕, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eebe358592e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286122, encodeId=f2ed1286122f1, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=络病研究推动微血管病变防治，创新成果赋能慢病管理, objectType=article, longId=735485, objectId=2affe35485b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2affe35485b4, replyNumber=0, likeNumber=52, createdTime=2022-08-11, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2affe35485b4, moduleTitle=络病研究推动微血管病变防治，创新成果赋能慢病管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2affe35485b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286123, encodeId=f3e91286123ed, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=胆管癌治疗困境有望打破，多款创新疗法迎来胆管癌治疗新希望！, objectType=article, longId=733740, objectId=6f73e33740d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f73e33740d4, replyNumber=0, likeNumber=52, createdTime=2022-07-30, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f73e33740d4, moduleTitle=胆管癌治疗困境有望打破，多款创新疗法迎来胆管癌治疗新希望！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f73e33740d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286121, encodeId=85b5128612111, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=不可手术腱鞘巨细胞瘤患者的福音！国内首个靶向创新药获突破性疗法认定, objectType=article, longId=733267, objectId=2ee2e33267bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ee2e33267bd, replyNumber=0, likeNumber=46, createdTime=2022-07-27, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ee2e33267bd, moduleTitle=不可手术腱鞘巨细胞瘤患者的福音！国内首个靶向创新药获突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ee2e33267bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286119, encodeId=ce79128611940, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=使用同一符号发表文章的侵权问题与创新驱动, objectType=article, longId=732783, objectId=c4a0e32783d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4a0e32783d3, replyNumber=0, likeNumber=32, createdTime=2022-07-21, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4a0e32783d3, moduleTitle=使用同一符号发表文章的侵权问题与创新驱动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4a0e32783d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286120, encodeId=c9351286120c4, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=糖尿病创新药物iGlarLixi又一临床研究SOLID正式启动，首例中国受试者已正式入组, objectType=article, longId=732402, objectId=8248e32402f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8248e32402f4, replyNumber=0, likeNumber=45, createdTime=2022-07-16, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8248e32402f4, moduleTitle=糖尿病创新药物iGlarLixi又一临床研究SOLID正式启动，首例中国受试者已正式入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8248e32402f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286117, encodeId=5893128611eda, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=吴家睿：基础研究的高风险导向型范式，助力“从0到1”的创新, objectType=article, longId=732018, objectId=26ffe3201813, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26ffe3201813, replyNumber=0, likeNumber=40, createdTime=2022-07-12, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26ffe3201813, moduleTitle=吴家睿：基础研究的高风险导向型范式，助力“从0到1”的创新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26ffe3201813)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286118, encodeId=4232128611843, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=周清教授 | 首个PD-1抑制剂头对头研究结果在2022 ASCO公布，中国创新药物彰显实力, objectType=article, longId=731997, objectId=1efbe3199786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1efbe3199786, replyNumber=0, likeNumber=0, createdTime=2022-07-12, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1efbe3199786, moduleTitle=周清教授 | 首个PD-1抑制剂头对头研究结果在2022 ASCO公布，中国创新药物彰显实力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1efbe3199786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286116, encodeId=3c3512861169a, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=2022上半年NMPA批准了32款创新药物, objectType=article, longId=731956, objectId=648ae319563a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=648ae319563a, replyNumber=0, likeNumber=39, createdTime=2022-07-11, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=648ae319563a, moduleTitle=2022上半年NMPA批准了32款创新药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=648ae319563a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286115, encodeId=ef16128611583, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=怎样推动“从0到1”的原始创新？这个比AlphaFold2更前瞻的研究当年坐足了“冷板凳”, objectType=article, longId=730519, objectId=961fe3051961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=961fe3051961, replyNumber=0, likeNumber=43, createdTime=2022-06-27, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=961fe3051961, moduleTitle=怎样推动“从0到1”的原始创新？这个比AlphaFold2更前瞻的研究当年坐足了“冷板凳”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=961fe3051961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286114, encodeId=672d1286114d0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=梅斯医学荣登“中国创新数字医疗榜TOP14”, objectType=article, longId=730221, objectId=7a0fe30221e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a0fe30221e5, replyNumber=0, likeNumber=40, createdTime=2022-06-24, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a0fe30221e5, moduleTitle=梅斯医学荣登“中国创新数字医疗榜TOP14”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a0fe30221e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1286113, encodeId=660612861131d, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, objectTitle=FDA批准非药物疗法NeuroMetrix治疗纤维肌痛，是一种创新神经调节医疗器械, objectType=article, longId=729774, objectId=849ee29774d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=849ee29774d3, replyNumber=0, likeNumber=55, createdTime=2022-06-18, rootId=0, userName=lilianxiang, userId=512a199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=849ee29774d3, moduleTitle=FDA批准非药物疗法NeuroMetrix治疗纤维肌痛，是一种创新神经调节医疗器械, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=849ee29774d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

创新

2020-05-29

lilianxiang (审核中...)

前往app查看评论内容

#创新#

中华医学会糖尿病学分会|南方医科大学沈洁教授：院内血糖管理模式探索及创新

2022-09-19

lilianxiang (审核中...)

前往app查看评论内容

#创新#

室性心律失常治疗策略全面升级，中医药创新给出中国化防治方案

2022-09-15

lilianxiang (审核中...)

前往app查看评论内容

#创新#

【日程更新】第四届创新药高峰论坛暨免疫治疗新药前沿论坛

2022-09-11

lilianxiang (审核中...)

前往app查看评论内容

#创新#

ESMO 2022：创新药物、创新疗法，精彩荟萃

2022-09-10

lilianxiang (审核中...)

前往app查看评论内容

#创新#

烧伤领域新动能！颠覆式创新产品PermeaDerm®实现创面修复

2022-09-06

lilianxiang (审核中...)

前往app查看评论内容

#创新#

明明是心脏病，怎么会中风？！都是房颤惹的祸——心脏专家呼吁早发现、早治疗，提高房颤创新药物可及性

2022-08-21

lilianxiang (审核中...)

前往app查看评论内容

#创新#

《梅斯药说》第十期药企数字化创新的蜕变和突围

2022-08-21

lilianxiang (审核中...)

前往app查看评论内容

#创新#

《梅斯药说》第五期 “聊聊肿瘤创新药那些事儿”

2022-08-21

lilianxiang (审核中...)

前往app查看评论内容

#创新#

上海生物医药创新企业自主研发的新冠 mRNA疫苗一期临床试验入组完毕

2022-08-16

lilianxiang (审核中...)

前往app查看评论内容

#创新#

络病研究推动微血管病变防治，创新成果赋能慢病管理

2022-08-11

lilianxiang (审核中...)

前往app查看评论内容

#创新#

胆管癌治疗困境有望打破，多款创新疗法迎来胆管癌治疗新希望！

2022-07-30

lilianxiang (审核中...)

前往app查看评论内容

#创新#

不可手术腱鞘巨细胞瘤患者的福音！国内首个靶向创新药获突破性疗法认定

2022-07-27

lilianxiang (审核中...)

前往app查看评论内容

#创新#

使用同一符号发表文章的侵权问题与创新驱动

2022-07-21

lilianxiang (审核中...)

前往app查看评论内容

#创新#

糖尿病创新药物iGlarLixi又一临床研究SOLID正式启动，首例中国受试者已正式入组

2022-07-16

lilianxiang (审核中...)

前往app查看评论内容

#创新#

吴家睿：基础研究的高风险导向型范式，助力“从0到1”的创新

2022-07-12

lilianxiang (审核中...)

前往app查看评论内容

#创新#

周清教授 | 首个PD-1抑制剂头对头研究结果在2022 ASCO公布，中国创新药物彰显实力

2022-07-12

lilianxiang (审核中...)

前往app查看评论内容

#创新#

2022上半年NMPA批准了32款创新药物

2022-07-11

lilianxiang (审核中...)

前往app查看评论内容

#创新#

怎样推动“从0到1”的原始创新？这个比AlphaFold2更前瞻的研究当年坐足了“冷板凳”

2022-06-27

lilianxiang (审核中...)

前往app查看评论内容

#创新#

梅斯医学荣登“中国创新数字医疗榜TOP14”

2022-06-24

lilianxiang (审核中...)

前往app查看评论内容

#创新#

FDA批准非药物疗法NeuroMetrix治疗纤维肌痛，是一种创新神经调节医疗器械

2022-06-18

科室
- - 订阅+
  - 更多科室
工具
服务